The LuViva® Advanced Cervical Scan continues to demonstrate the
capability to screen the general population for cervical cancer and to
eliminate unnecessary testing for women who are screened by other
methods, according to recent studies presented at the 25 th
Turkish Society of Gynecology Oncology Congress.
Cerus Corporation (NASDAQ:CERS) announced today that its European Phase
3 clinical trial of red blood cells treated with the INTERCEPT Blood
System for acute anemia in cardiovascular surgery patients met the
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 2
clinical trial of red blood cells treated with the INTERCEPT Blood
System met its primary endpoint, with preliminary analysis demonstrating
that greater than 75 percent of treated red blood cells continued to
circulate 24 hours following transfusion.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.